دورية أكاديمية
أعرض في EDS

Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019.

التفاصيل البيبلوغرافية
العنوان: Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019.
المؤلفون: Clopper BR; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA. Electronic address: oyx5@cdc.gov., Zhou Y; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA., Tannis A; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA., Staat MA; Division of Infectious Diseases, Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Rice M; Division of Infectious Diseases, Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Boom JA; Immunization Project, Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, TX., Sahni LC; Immunization Project, Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, TX., Selvarangan R; Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO., Harrison CJ; Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO; Department of Infectious Diseases, UMKC, Kansas City, MO., Halasa NB; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN., Stewart LS; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN., Weinberg GA; Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY., Szilagyi PG; Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY., Klein EJ; Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA., Englund JA; Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA., Rha B; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA., Lively JY; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA., Ortega-Sanchez IR; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA., McMorrow ML; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA; US Public Health Service, Rockville, MD., Moline HL; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA; US Public Health Service, Rockville, MD.
المصدر: The Journal of pediatrics [J Pediatr] 2024 Aug; Vol. 271, pp. 114045. Date of Electronic Publication: 2024 Mar 30.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 0375410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6833 (Electronic) Linking ISSN: 00223476 NLM ISO Abbreviation: J Pediatr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: St. Louis, MO : Mosby
مواضيع طبية MeSH: Respiratory Syncytial Virus Infections*/economics , Respiratory Syncytial Virus Infections*/prevention & control , Respiratory Syncytial Virus Infections*/epidemiology , Emergency Service, Hospital*/economics , Emergency Service, Hospital*/statistics & numerical data , Hospitalization*/economics , Hospitalization*/statistics & numerical data, Humans ; Infant ; Child, Preschool ; Female ; Male ; United States/epidemiology ; Prospective Studies ; Health Care Costs/statistics & numerical data ; Infant, Newborn ; Hospital Costs/statistics & numerical data ; Respiratory Syncytial Virus Vaccines/economics ; Emergency Room Visits
مستخلص: Objective: To assess medical costs of hospitalizations and emergency department (ED) care associated with respiratory syncytial virus (RSV) disease in children enrolled in the New Vaccine Surveillance Network.
Study Design: We used accounting and prospective surveillance data from 6 pediatric health systems to assess direct medical costs from laboratory-confirmed RSV-associated hospitalizations (n = 2007) and ED visits (n = 1267) from 2016 through 2019 among children aged <5 years. We grouped costs into categories relevant to clinical care and administrative billing practices. We examined RSV-associated medical costs by care setting using descriptive and bivariate analyses. We assessed associations between known RSV risk factors and hospitalization costs and length of stay using χ 2 tests of association.
Results: The median cost was $7100 (IQR $4006-$13 355) per hospitalized child and $503 (IQR $387-$930) per ED visit. Eighty percent (n = 2628) of our final sample were children aged younger than 2 years. Fewer weeks' gestational age was associated with greater median costs in hospitalized children (P < .001, ≥37 weeks of gestational age: $6840 [$3905-$12 450]; 29-36 weeks of gestational age: $7721 [$4362-$15 274]; <29 weeks of gestational age: $9131 [$4518-$19 924]). Infants born full term accounted for 70% of the total expenditures in our sample. Almost three quarters of the health care dollars spent originated in children younger than 12 months of age, the primary age group targeted by recommended RSV prophylactics.
Conclusions: Reducing the cost burden for RSV-associated medical care in young children will require prevention of RSV in all young children, not just high-risk infants. Newly available maternal vaccine and immunoprophylaxis products could substantially reduce RSV-associated medical costs.
Competing Interests: Declaration of Competing Interest Each participating institution received grant support from the US Centers for Disease Control and Prevention (CDC) for the conduct of this work (CDC-RFA-IP16-004). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the CDC. The following are authors’ declarations of competing interests. M.S.: investigator for the Pfizer MATISSE maternal RSV vaccine trial; CDC cooperative agreement funding; grants/contracts with the National Institutes of Health (NIH), Merck, Cepheid; and royalties from UpToDate. J.B.: CDC cooperative agreement funding. R.S.: research funds from Merck; advisory board GlaxoSmithKline; cooperative agreement funding from CDC; grants from Hologic, BioFire, Becton Dickson, Luminex, and Cepheid. C.H.: cooperative agreement funding from CDC; grants from GlaxoSmithKline, Merck, Pfizer. N.H.: cooperative agreement funding from CDC; grants from Sanofi, Quidel, Merck. G.W.: cooperative agreement funding from CDC; grants from NY State Dept. of Health AIDS Institute; honoraria from Merck. P.S.: cooperative agreement funding from CDC. E.K.: cooperative agreement funding from CDC. J.E.: cooperative agreement funding from CDC; grants from AstraZeneca, GlaxoSmithKline, Pfizer, Merck; consulting fees from AbbVie, AstraZeneca, Ark Biopharma, Meissa Vaccines, Moderna, Sanofi Pasteur, Shinogi, and GlaxoSmithKline. All other authors declare no competing interests.
(Published by Elsevier Inc.)
معلومات مُعتمدة: U01 IP000460 United States IP NCIRD CDC HHS; U01 IP001057 United States IP NCIRD CDC HHS; U01 IP001154 United States IP NCIRD CDC HHS
فهرسة مساهمة: Keywords: RSV; cost; emergency department; hospitalizations; pediatrics
المشرفين على المادة: 0 (Respiratory Syncytial Virus Vaccines)
تواريخ الأحداث: Date Created: 20240401 Date Completed: 20240711 Latest Revision: 20240730
رمز التحديث: 20240730
DOI: 10.1016/j.jpeds.2024.114045
PMID: 38561048
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-6833
DOI:10.1016/j.jpeds.2024.114045